. . . . . "NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of LOXO-101 (Larotrectinib) in Patients With Tumors Harboring Actionable NTRK Fusions"@en . . . . . . . "Larotrectinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With NTRK Fusions (A Pediatric MATCH Treatment Trial)"@en . . . "klinisch onderzoek"@nl . . . . . . "ensayu cl\u00EDnicu"@ast . . . . . . . . . . . . "2017-07-24T00:00:00Z"^^ . "2024-09-30T00:00:00Z"^^ . . . . . . . . . . . . "12"^^ . "Larotrectinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With NTRK Fusions (A Pediatric MATCH Treatment Trial)"@en . . . . . . . . . . . . . . . . . "clinical trial"@en . . . . . . . . . . . . . . . . "NCT03213704" . . . . . . . . . "21"^^ . . "Larotrectinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With NTRK Fusions (A Pediatric MATCH Treatment Trial)"@en . . . . . . . . . . . . . "49"^^ . . . . . . . . . . . . . . "\u043A\u043B\u0456\u043D\u0456\u0447\u043D\u0435 \u0432\u0438\u043F\u0440\u043E\u0431\u0443\u0432\u0430\u043D\u043D\u044F"@uk . . . . . . . .